Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies
1 clinical trials · Condition
| Record | Firm | Date |
|---|---|---|
| Ribociclib (LEE011) Rollover Study for Continued Access (NCT02934568) | Novartis Pharmaceuticals | 2016-12-15 |
Track Continued Access to Study Treatment(s), Cancers With a Mass, Bulky Tumor, Nodule, Lump, Advanced Cancer, Advanced Solid Tumors, Advanced Solid Malignancies automatically
Every clearance here is in the API, with alerts when new ones post.